Related Experiment Video

Updated: Jun 23, 2025

Preparation and Characterization of SDF-1α-Chitosan-Dextran Sulfate Nanoparticles
12:00

Preparation and Characterization of SDF-1α-Chitosan-Dextran Sulfate Nanoparticles

Published on: January 22, 2015

12.4K

Chitosan-Derived Nanocarrier Polymers for Drug Delivery and pH-Controlled Release in Type 2 Diabetes Treatment

Shanshan Guo1, Hua Li2

  • 1Department of Endocrinology, Zhabei Central Hospital, Shanghai, China. 13918457276@163.com.

Journal of Fluorescence
|June 18, 2024
PubMed

Insights

This study developed a smart chitosan nanocarrier (FA-CMCS@1-CrPc) for Type 2 Diabetes Mellitus (T2DM) treatment. It offers controlled drug release, pH sensitivity, and enhanced fluorescence detection for improved T2DM therapy.

Area of Science:

  • Biomaterials Science
  • Nanotechnology
  • Endocrinology

Background:

  • Type 2 Diabetes Mellitus (T2DM) is a growing global health concern, marked by insulin resistance and insufficient insulin secretion.
  • Current treatments face challenges with drug toxicity, solubility, and controlled release of advanced glycation end products (AGEs).
  • Chitosan-based nanocarriers are promising for drug delivery due to their biocompatibility and tunable properties.

Purpose of the Study:

  • To design and synthesize an intelligent, fluorescence-pH sensitive nanopolymer material for T2DM treatment.
  • To develop a chitosan-based nanocarrier (FA-CMCS@1-CrPc) for controlled delivery of therapeutic agents and AGEs.
  • To evaluate the nanocarrier's characteristics, drug release kinetics, and efficacy in an in vitro T2DM model.

Main Methods:

  • Synthesis of folic acid-conjugated carboxymethyl chitosan (FA-CMCS) nanocarriers loaded with drug 1 and chromium phthalocyanine (CrPc).
  • Characterization using FTIR, SEM, TEM, TGA, and BET analysis.
  • In vitro evaluation of pH-dependent drug release, fluorescence detection sensitivity, and effects on insulin-resistant cells.

Main Results:

  • Successful synthesis of FA-CMCS@1-CrPc nanocarriers with high specific surface area, biocompatibility, and fluorescence response.
  • Demonstrated controlled and pH-regulated drug release capabilities.
  • Achieved high sensitivity in detecting trace drug release and showed potential in regulating glucose degradation and AGE-RAGE pathways in vitro.

Conclusions:

  • FA-CMCS@1-CrPc represents a novel, intelligent nanoplatform for T2DM drug delivery.
  • The nanocarrier offers controlled release, sensitive fluorescence monitoring, and potential for AGE-RAGE regulation.
  • This system provides a foundation for developing advanced therapeutic strategies for T2DM.
Keywords:
ChitosanFluorescenceNanoType 2 diabetes

More Related Videos

Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres09:31

Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres

Published on: November 5, 2016

7.3K
Injectable Supramolecular Polymer-Nanoparticle Hydrogels for Cell and Drug Delivery Applications09:39

Injectable Supramolecular Polymer-Nanoparticle Hydrogels for Cell and Drug Delivery Applications

Published on: February 7, 2021

7.8K

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
188
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
257
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
316
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
188
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
152
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
170